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Abstract: Tumor cells exhibit therapeutic stress resistance-associated secretory phenotype involving
extracellular vesicles (EVs) such as oncosomes and heat shock proteins (HSPs). Such a secretory
phenotype occurs in response to cell stress and cancer therapeutics. HSPs are stress-responsive
molecular chaperones promoting proper protein folding, while also being released from cells
with EVs as well as a soluble form known as alarmins. We have here investigated the secretory
phenotype of castration-resistant prostate cancer (CRPC) cells using proteome analysis. We have also
examined the roles of the key co-chaperone CDC37 in the release of EV proteins including CD9 and
epithelial-to-mesenchymal transition (EMT), a key event in tumor progression. EVs derived from
CRPC cells promoted EMT in normal prostate epithelial cells. Some HSP family members and their
potential receptor CD91/LRP1 were enriched at high levels in CRPC cell-derived EVs among over
700 other protein types found by mass spectrometry. The small EVs (30–200 nm in size) were released
even in a non-heated condition from the prostate cancer cells, whereas the EMT-coupled release of
EVs (200–500 nm) and damaged membrane vesicles with associated HSP90α was increased after heat
shock stress (HSS). GAPDH and lactate dehydrogenase, a marker of membrane leakage/damage, were
also found in conditioned media upon HSS. During this stress response, the intracellular chaperone
CDC37 was transcriptionally induced by heat shock factor 1 (HSF1), which activated the CDC37 core
promoter, containing an interspecies conserved heat shock element. In contrast, knockdown of CDC37
decreased EMT-coupled release of CD9-containing vesicles. Triple siRNA targeting CDC37, HSP90α,
and HSP90β was required for efficient reduction of this chaperone trio and to reduce tumorigenicity of
the CRPC cells in vivo. Taken together, we define “stressome” as cellular stress-induced all secretion
products, including EVs (200–500 nm), membrane-damaged vesicles and remnants, and extracellular
HSP90 and GAPDH. Our data also indicated that CDC37 is crucial for the release of vesicular proteins
and tumor progression in prostate cancer.
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1. Introduction
Tumor cells are often exposed to various stresses such as immune/inflammatory stress,
therapeutics [1], hypoxia [2–4], acidification, oxidative stress [5,6], starvation [7], nutrient stress [8], heat
and cold [9,10], thermal stress, replication stress [11], endoplasmic reticulum (ER) stress, neurotoxic
stress [12], genotoxic (DNA damage) [13] and proteotoxic stress [14,15]. Heat shock proteins (HSPs)
were originally found to be induced upon heat shock stress (HSS) [9]. Later studies have revealed
that other types of stresses can also induce HSPs, including hypoxia [16] and nutrient starvation [7].
HSPs are molecular chaperones that assist in proper protein folding and re-folding in the cells,
playing stress-resistant roles in anti-apoptotic activity [9] against radiation therapy, chemotherapy,
and immunotherapy. It has been shown that HSPs are often increased in tumor cells and are involved
in the properties of tumor progression such as increased migration, invasion, and metastasis [17,18].
Additionally, extracellular HSPs are released from cells with vesicles as well as a soluble form [4,19,20].
Notably, HSPs and vesicles were co-released upon cell stress and cell damage such as molecular
targeted therapeutic stress [21,22], anticancer therapeutic DNA damage stress [23,24], and HSS [25,26].
Extracellular HSPs are also known as alarmin or damage-/danger-associated molecular patterns
(DAMP) that are released from cells upon tissue damage [27,28].
Extracellular vesicle (EV) is the generic term for particles naturally released from the cell that are
delimited by lipid bilayer and cannot replicate, i.e., do not contain a functional nucleus [29]. EVs often
contain a variety of molecular cargos such as proteins, small and large RNAs, DNA, lipid, glycans,
mineral such as calcium, and metabolites that are secreted by cells [30–33]. Major EV subtypes are
endosome-origin “exosomes” and plasma membrane-derived “ectosomes” (also known as microparticles
or microvesicles) [34,35]. Authors have been urged to consider use of operational terms for EV subtypes
that refer to physical characteristics of EVs, such as size; small EVs (sEV) and medium/large EVs
(m/lEVs), with ranges defined, for example, < 200 nm (small) or > 200 nm (large and/or medium),
respectively [29,36,37]. Additionally, according to the history of discoveries and characteristics of EVs,
additional types of EVs have been reported consisting of oncosomes (named after oncogenic EVs) [38,39],
large oncosomes (1–10 µm) [40], matrix vesicles [41], migrasomes [42], exopheres (≈4 µm), exomeres
(≈35 nm), and bacterial outer membrane vesicles (OMV) [43]. These vesicles often play basic roles in
discarding molecules unfavorable for cells [44], while also mediating intercellular communication by
transferring their cargos to recipient cells or organs in local and/or distant tissues [45]. Among various
concepts of EVs, oncosomes have been shown to promote processes in tumor progression such as
epithelial-to-mesenchymal transition (EMT) by transferring oncogenic molecules [46–48]. In addition,
the enhancement of EMT properties was often coupled with increased release of EVs [22,49]. These facts
prompted us to make a concept of EMT-coupled vesicle release.
Among many molecular cargos, HSPs are major signatures often found within sEV such as
exosomes, ectosomes, and oncosomes [4,19,20,27]. According to the minimal information for studies of
extracellular vesicles 2018 (MISEV2018), EV markers are categorized into five categories and the category
2 (cytosolic proteins recovered in EVs) includes heat shock cognate 70 (HSC70/HSPA8: essential for
autophagy), HSP70, and HSP90β (HSP90AB1/HSP84), while category 4 (transmembrane, lipid-bound,
and soluble proteins associated to other intracellular compartments than plasma membrane/endosomes)
includes ER chaperones such as Grp94/HSP90B and BiP/HSPA5 [29]. Moreover, sEV derived from
oral cancer cells contained a variety of HSPs, including HSP90α (HSP90AA1), HSP90β, TRAP1
(mitochondrial HSP90), HSP105, HSP70 (HSP72/HSPA1A and HSP70B’/HSPA6), GRP78/HSPA5 (ER
chaperone), and HSC70 [20]. Among these HSPs, two HSP90 isoforms (HSP90α and HSP90β) were
enriched in sEV derived from high metastatic cancer cells compared to low metastatic ones [20].
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The high expression levels of HSP90α/β are correlated with poor prognosis in patients suffering from
head and neck cancers [20]. Several studies, including ours, have indicated that HSP90 is essential in
stress resistance in cancer cells [19,50–52]. Cell division control 37 (CDC37), a key co-chaperone for
HSP90, is highly expressed in castration-resistant prostate cancer (CRPC) cells as compared to normal
prostate epithelial cells or prostate adenocarcinoma cells [4,53]. However, less is known regarding
stress-responsive co-release of EVs and HSP90 from the resistant cells. We have therefore addressed
this deficiency in this study.
The growth of prostate cancers is often androgen-dependent, requiring factors such as testosterone
and dihydrotestosterone (DHT) [54]. Therefore, androgen depletion therapy (ADT), also called
hormone therapy, is often effective in prostate cancers. However, some types of prostate cancer are
resistant to ADT and known as CRPC, a prostatic type of neuroendocrine tumors (NET), and this is
also a phenotype found in aggressive pancreatic cancer [55–57]. Notably, tumorigenicity and EMT
are key properties for recurrence and metastasis in such aggressive, resistant cancers [58,59]. In the
androgen insensitivity, intracellular kinase signaling pathways are given higher priorities required for
tumor progression. Indeed, CDC37, the protein kinase-specialized (kinome) co-chaperone of HSP90,
was highly expressed in the CRPC cells as compared to the prostate adenocarcinoma cells and normal
prostate epithelial cells [60]. CDC37 plays a fundamental role in chaperoning almost all members
of the protein kinase family and participates in cancer by maintaining the activity of protein kinases
involved in cell proliferation and transformation [61,62]. These include tyrosine kinases such as Src [63],
and serine/threonine kinases in the Raf-ERK pathway [64], Akt, the inhibitor of NF-κB kinase (IKK) [65],
and cyclin-dependent kinase 4 (CDK4) [66,67]. CDC37 functions primarily in a complex with HSP90 to
mediate the three-dimensional (3D) folding and structural integrity of client proteins kinases [63,68].
CDC37 is particularly significant in prostate cancer as its overexpression leads to spontaneous prostate
carcinogenesis in transgenic mice [69]. It has also been suggested that the high levels of oncogenic
proteins present in most cancers make them dependent on molecular chaperones, a state referred to
as “chaperone addiction” [61]. Thus, because of their large protein clienteles, the CDC37-HSP90 axis
offers a critical target for inactivating multiple oncogenic pathways. Consequently, the inhibition of
HSP90 in cancer is currently a major area of research [70,71]. However, less is known regarding the
role of CDC37 in EV release and we have addressed this deficiency in this study.
In the present study, we therefore aimed (i) to reveal proteome signatures of EVs derived from
CRPC cells, and (ii) to unveil stress-responsive vesicle release potentially coupled with resistant
tumorigenicity in cancer.
2. Materials and Methods
2.1. Cell Culture
PC-3, a CRPC cell line, DU-145, a prostate adenocarcinoma cell line, and PNT2, an immortalized
prostate epithelial cell line, were maintained in RPMI1640 medium with 5% to 10% FBS as described
previously [4,60,72,73]. RWPE1, a human normal prostate cell line, was maintained in keratinocyte
serum-free medium (ThermoFisher, Waltham, MA, USA) supplemented with recombinant human
epidermal growth factor (hEGF) and bovine pituitary extract. Human prostate epithelial cells (PrEC)
were maintained in PrEBM basal medium supplemented with bovine pituitary extract, triiodothyronine,
insulin, hEGF, hydrocortisone, transferrin, epinephrine, gentamicin sulfate-amphotericin, and retinoic
acid (Lonza, Basel, Switzerland).
2.2. Heat Shock Stress
For HSS, the medium was replaced to incubated medium at 43 or 37 ◦C and then put in a water
bath at 43 or 37 ◦C, as described previously [25,74]. After HSS, cells were washed with PBS (-) and
cultured in serum-free media. Cellular photomicrographs were taken at 24 h after medium replacement
by using Floid Cell Imaging Station (ThermoFisher).
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2.3. Extracellular Vesicle and Non-EV Fractions
For HSS experiments, after the above-mentioned HS, cells were washed with PBS and cultured
in serum-free media for 24 h and then conditioned media was collected. At the time of harvest,
the numbers of cells were counted using Countess (ThermoFisher, Waltham, MA, USA) and whole cell
lysate was prepared as described below. Otherwise, cultured cells were washed with Hanks’ balanced
salt solution (HBSS), and then further cultured in serum-free medium for 1 or 2 days. EV fraction
was prepared using a modified polymer-based precipitation (PBP) method. Briefly, the conditioned
medium was centrifuged at 2000× g for 30 min at 4 ◦C to remove cell debris. For studies of knockdown
and EMT, the supernatant was filtered with a 0.2-µm syringe filter. Otherwise, the filter was not used.
The supernatant was collected and centrifuged at 10,000× g for 30 min at 4 ◦C. The supernatant was
collected and applied to an Amicon Ultra-15 Centrifugal Filter Device MW.100k (Merck, Kenilworth,
NJ, USA) to concentrate the pre-EV fraction to less than 1 mL and to separate non-EV soluble fraction.
The pass-through was applied to an Amicon Ultra-4 Centrifugal Filter Device MW.10k (Merck) to
concentrate the non-EV soluble fraction. Total Exosome Isolation Reagent (ThermoFisher) was applied
to the pre-EV fraction and incubated overnight at 4 ◦C. The precipitated EVs were collected by
centrifugation at 10,000× g for 60 min at 4 ◦C. For biological assays, the EV fractions were eluted in
100 µL PBS (-). For protein assay, 10 × RIPA buffer containing 10% NP-40, 1% SDS, 5% deoxycholate
in PBS (-), and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) was added to the
EV fraction, incubated on ice for 15 min. The EV-derived protein samples were quantified with a
principle of bicinchoninic acid (BCA) method using Micro BCA protein assay system (ThermoFisher).
EV protein concentrations per cell were calculated at the time points of harvest.
2.4. Mass Spectrometry
EV fraction was incubated in the presence of 1% SDS and 2.5 mM Tris (2-carboxyethyl)phosphine
hydrochloride (ThermoFisher) for 10 min at 85 ◦C followed by alkylation with 12.5 mM iodoacetamide
(Sigma-Aldrich) for 15 min at room temperature. Proteins were precipitated with acetone for 2 h
at −30 ◦C and the resulting pellet was dispersed in 100 mM ammonium bicarbonate by ultrasonic
treatment (three times for 30 s with intervals of 30 s) with a Bioruptor (Diagenode, Liège, Belgium).
The protein suspension was subjected to digestion with trypsin (1 µg; Wako) for 14 h at 37 ◦C. Resulting
peptides were analyzed by a QExactive mass spectrometer that was coupled with nano-LC (AdvanceLC;
Michrom BioResources, Auburn, CA, USA) via a nano-electrospray source with a column oven set at
37 ◦C (AMR Inc., Gifu, Japan). Samples were injected to pre-column [L-column micro: 0.3 mm inner
diameter, 5 mm length; Chemicals Evaluation and Research Institute (CERI), Japan] and separated
by in-house made 20 cm column (inner diameter 100 µm, 3 µL-column; CERI, Japan) with a linear
gradient (5%–30% B for 110 min, 30%–90% B for 1 min, and 90% B for 10 min, A: 0.1% formic acid, 2%
acetonitrile, B: 0.1% formic acid, 99.9% acetonitrile) at a flow rate of 250 nL/min. The QExactive was
operated in data-dependent acquisition mode. Scan ranges were set at m/z 375−1600 for MS spectra
and m/z 200−2000 for MS/MS spectra, respectively. MS spectra were acquired at a resolution of 70,000
at m/z 400 after accumulation to a target value of 1 × 106 with the maximum ion injection times for
60 msec. Up to the top 10, most abundant ions with charge 2+ or 3+ from the survey scan were selected
with an isolation window of 1.5 h and fragmented by high energy collisional dissociation (HCD) with
normalized collision energies of 25. MS/MS spectra were acquired at a resolution of 17,500 at m/z 400
after accumulation to a target value of 5 × 104 with the maximum ion injection times for 120 msec.
The acquired MS/MS spectra were analyzed by Proteome Discoverer 1.4 with the Mascot algorithm
ver. 2.6.0 using an IPI human database (ver. 3.8.7). The search was performed with the following
parameters: trypsin was selected as an enzyme used, the number of missed cleavages allowed was set
as 3, and carbamidomethylation on Cys was selected as a fixed modification. Oxidized methionine was
searched as variable modifications. Precursor mass tolerances were 10 ppm and tolerance of MS/MS
ions was 0.02 Da.
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2.5. Electron Microscopy
TEM was carried out as described previously [3,20,48]. A 400-mesh copper grid coated with
formvar/carbon films was hydrophilically treated. The EV suspension (5–10 µL) was placed on parafilm,
and the grid was floated on the EV liquid and left for 15 min. The sample was negatively stained
with 2% uranyl acetate solution for 2 min. EVs including exosomes on the grid were visualized with
5000–20,000 times magnification with an H-7650 transmission electron microscope (Hitachi, Tokyo,
Japan) at Central Research Laboratory, Okayama University Medical School. To determine the size of
EVs, TEM images were analyzed using Image J software. The diameters of 50 EVs were measured by
taking the length of the widest point of each EV. Objects were limited to those greater than 50 nm.
2.6. EV Counting and Diameter Distribution Analysis
For EV diameter distribution analysis, 40 µL of EV fraction solved in PBS (-) was analyzed
in a range between 0 and 10,000 nano-diameters in Zetasizer nano ZSP (Malvern Panalytical, UK)
as described previously [3,20]. Alternatively, the diameter distribution of EVs was analyzed using
ELS-8000 (Otsuka Electronics, Hirakawa, Japan) for a range of 1–10,000 nm with a setting of sidecut
L20 as described previously [48].
For EV counting and diameter distribution analysis, the EV fractions were diluted 10-fold,
passed through 0.22 µm-pore filters, and then analyzed using qNano particle analyzer (Meiwa Fosis,
Osaka, Japan).
2.7. Cytotoxic LDH Assay
Cytotoxicity was measured using the index of lactate dehydrogenase (LDH) release from the cells
and was expressed as a percentage of total cellular LDH activity. LDH activity was measured using
an LDH cytotoxicity assay kit according to the manufacturer’s instructions (Nacalai Tesque, Kyoto,
Japan). Cells were seeded at 5000 cells/well in 96-well plate and pre-cultured in RPMI1640 medium
containing 10% FBS for 1 or 2 days. After the above-mentioned HSS for 0.5, 1.5, or 3 h, culture media
were collected for the first LDH assay. Cells were washed with PBS (-), cultured in serum-free media
for 24 h, and then conditioned media were collected. The collected culture media were transferred to
another 96-well plate and incubated with substrate solution at RT for 20 min. The stop solution was
added and absorbance (490 nm) was measured.
2.8. Cellular Morphology
Phase contrast cell photomicrographs were taken using Olympus CK30 equipped with a Digital
Microscope Eyepiece Model MA88 (Premiere®) as described previously [22]. The rates of occurrence
of cells with projections and round-shaped cells in cellular photomicrographs were counted by two
researchers as blind experiments.
2.9. Promoter Analysis and Heat Shock Element
Promoter analysis was performed as described previously [60,75,76]. Briefly, DNA sequences
of 5’-flanking regions and gene bodies (−5000 to +1000) of Cdc37 in human (Homo sapiens), mouse
(Mus musculus), rat (Rattus norvegicus), and fission yeast (S. pombe) were obtained from the Eukaryotic
Promoter Database (EPD) [77]. Heat shock elements (HSE) based on the consensus sequence
5’-GAAxxTTCxxGAA-3’ and the reverse sequence 5’-TTCxxGAAxxTTC-3’ were searched using EPD.
2.10. Plasmid Constructs and Luciferase Assay
The CDC37 promoter-luciferase reporter constructs (500+UTR and 200+UTR) [60],
the overexpression constructs of heat shock factor 1 (HSF1) and dominant-negative (DN)-HSF1 [74],
plasmid DNA co-transfection, and luciferase assay were described previously [60,74,78]. Briefly,
cells were cultured in 96-well plates and a plasmid (25 ng reporter, 100 ng effector) was transfected
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with 0.4 µL FuGENE HD (Roche, Basel, Switzerland) per well at a cell confluence level of 50%–70%.
The medium was changed at 16–20 h after transfection. At 40–48 h after transfection, 70 µL of the
medium was aspirated, then 30 µL of Bright-Glo reagent (Promega, Madison, WI, USA) was added
and mixed by pipetting. Cells were incubated for 5 min at 37 ◦C. The lysate (40 µL) was transferred to
a 96-well white plate for measurement of luminescence.
2.11. RNA Interference
We designed siRNA sequences targeting mRNA of CDC37, HSP90AA1, or HSP90AB1 (Table 1).
For targeting each mRNA, a mixture of two types of siRNA duplex was used. The control non-targeting
siRNA was purchased from Nippon Gene. Cells were transfected with siRNA using Lipofectamine
RNAi MAX (Thermo Fisher). For single or double knockdown, cells were cultured in a 6-cm dish and
27 pmol siRNA was transfected with 8 µL of Lipofectamine RNAi MAX per dish for 24 h. The medium
was replaced with serum-free fresh medium and the EV and whole cell lysate (WCL) were prepared at
48 h post-transfection.
Table 1. List of sequences of siRNA.
Name of siRNA Oligonucleotide Sequence (5’ to 3’)
hCDC37.NM7065-433 sense gcaagaaggagaagagcauTT
hCDC37.NM7065-433 antisense augcucuucuccuucuugcTT
hCDC37.NM7065-584 sense gaaacagaucaagcacuuuTT
hCDC37.NM7065-584 antisense aaagugcuugaucuguuucTT
hHSP90AA1.NM5348-415 sense gcugcauauuaaccuuauaTT
hHSP90AA1.NM5348-415 antisense uauaagguuaauaugcagcTT
hHSP90AA1.NM5348-2010 sense caaacauggagagaaucauTT
hHSP90AA1.NM5348-2010 antisense augauucucuccauguuugTT
hHSP90AB1-NM_001271971.1-1353 sense cagaagacaaggagaauuaTT
hHSP90AB1-NM_001271971.1-1353 antisense uaauucuccuugucuucugTT
hHSP90AB1-NM_001271971.1-1754 sense gaagagagcaaggcaaaguTT
hHSP90AB1-NM_001271971.1-1754 antisense acuuugccuugcucucuucTT
For triple knockdown, electroporation-mediated transfection was optimized and performed as
described previously [3,60]. To optimize electroporation for each cell type, cells (1 × 105 to 1 × 106 cells),
siRNA (40 pmol total), and serum-free medium were mixed to 100 µL total in a green cuvette with a
1-mm gap (NepaGene, Ichikawa, Tokyo, Japan) and set to NEPA21 Super Electroporator (NepaGene).
Poring pulse was optimized between 100 V and 300 V for 2.5 or 5.0 msec pulse length twice with a
50 msec interval between the pulses and 10% decay rate with + polarity, as shown in a Supplementary
Materials. The transfer pulse condition was five pulses at 20 V for 50 msec pulse length with 50 msec
interval between the pulses and 40% decay rate with +/− polarity. After electroporation, cells were
recovered in serum-containing media. PC-3 (5 × 105 cells) was transfected with 40 pmol siRNA with
poring pulse at 175 V for 2.5 msec pulse length twice and then cultured for 4 days for Western blotting.
Alternatively, transfected PC-3 was cultured for 5 days and 1 × 106 cells were subcutaneously injected
to each SCID mouse as described below.
2.12. Whole Cell Lysate
Cells were lysed as described previously [79,80]. Briefly, cells were cultured until being
sub-confluent and then washed with PBS (-), treated with 150–200 µL/dish of a 1× RIPA buffer
containing 1% NP-40, 0.1% SDS, and 0.5% deoxycholate, and a protease inhibitor cocktail (Sigma) in PBS
(-), and collected by using a cell scraper. Cells were further lysed by a 25G needle-syringe for 10 strokes
and then incubated for 30 min on ice. For protein extraction from RWPE1 cells, cell lysis buffer (150 mM
NaCl, 1% NP-40, 1% Na-deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5, 1 mM PMSF, 25 mM NaF, 2%
Triton X-100) containing protease inhibitor cocktail was used. The lysate was centrifuged at 12,000× g
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for 20 min at 4 ◦C and the supernatant was used as a WCL. The WCL was diluted 10-fold and protein
concentration was measured by using the Micro BCA protein assay system (ThermoFisher).
2.13. Western Blotting
Western blotting was performed as described previously [20,60]. In the HSS studies, protein
samples corresponding to the same cell numbers were applied to each lane. The protein amount and
cell numbers used in each experiment are described in Supplementary Materials. Briefly, the protein
amount equivalent to 1 × 105, 5 × 105, 1 × 106, or 3 × 106 cells were loaded for analysis of EV
fractions. The protein amount equivalent to 2 × 104 or 6 × 104 cells were loaded for analysis of WCL.
The protein amount equivalent to 3 × 105 cells were used for protein analysis in the non-EV cell culture
supernatant. Protein samples were reduced with β-mercaptoethanol except for CD9 Western blotting.
The samples were separated by SDS-PAGE in 4%–20% TGX-GEL (BioRad, Hercules, CA, USA) or 10%
polyacrylamide gel and transferred to PVDF membrane using a semi-dry method. Anti-CDC37 (1:1000;
Cell Signaling Technology (CST), Danvers, MA), anti-HSP90α (1:1000; GeneTex, Irvine, CA, USA),
anti-HSP90β (1:1000; GeneTex), anti-CD9 (1:10,000 or 1:1000; MBL, Nagoya, Japan), anti-actin (1:200;
Sigma), and HRP-conjugated anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:5000;
FujiFilm Wako, Osaka, Japan) antibodies were used. The blots were visualized with ECL Plus Western
blotting substrate (Pierce) or Immobilon Forte Western HRP substrate (Millipore, Burlington, MA, USA).
For studies of knockdown, EV addition, and EMT, equal amounts of protein samples in each
Western blotting analysis (each 3µg of protein samples for analysis of EV-CD9 and EV-GAPDH, and each
15µg of protein samples for analysis of cellular proteins). For double knockdown studies, each 10µg
of protein samples for analysis of HSP90α, HSP90β, CDC37, E-cadherin, vimentin, and GAPDH was
loaded. Protein samples were reduced with β-mercaptoethanol except for CD9 Western blotting,
separated by SDS-PAGE in 4%–20% TGX-GEL (BioRad) or 10% polyacrylamide gel, and transferred to
PVDF membrane using a semi-dry method. For EV addition studies, each 10µg of protein samples
for analysis of E-cadherin, N-cadherin, and GAPDH was loaded. Protein samples were reduced with
β-mercaptoethanol, separated by SDS-PAGE in 8% polyacrylamide gel, and transferred to PVDF
membrane using a wet method. In addition to the above-mentioned antibodies, anti-E-cadherin (1:1000,
CST), N-cadherin (1:1000, CST), and anti-Vimentin (1:1000, CST) antibodies were used. The blots
were visualized with ECL Plus Western blotting substrate (Pierce, ThermoFisher) or Immobilon Forte
western HRP substrate (Millipore).
The images were quantified with the internal control of the actin or GAPDH protein levels and
relative quantitative analysis was carried out based on the image band density ratio using ImageJ
software (NIH, Bethesda, MD, USA). The quantitative values were shown in Supplementary Materials.
2.14. Tumor Xenograft
All animals were held under specific pathogen-free conditions. For chaperone triple-depletion,
PC-3 cells (5 × 105) were transfected with siRNA targeting mRNA of CDC37, HSP90α and HSP90β
(17 pmol each) via electroporation and cultured for 5 days. PC-3 transfected with siRNA (1 × 106 cells)
was subcutaneously injected to each back of male SCID mice at 6- to 7-weeks old. The major axis (a)
and minor axis (b) of tumors were measured with a caliper once a week until the day 99 post-injection
period. The tumors were deemed to be ellipsoid and the volumes were calculated with a formula
as follows: a tumor volume (V)
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The images were quantified with the internal control of the actin or GAPDH protein levels and 
relative quantitative analysis was carried out based on the image band density ratio using ImageJ 
software (NIH, Bethesda, MD, USA). The quantitative values were shown in supplementary figures. 
2.14. Tumor Xenograft 
All animals wer  held under spe ific pathogen-free conditions. For chaperone tripl -d pletion, 
PC-3 cells (5 × 105) were transf cted with siRNA targeting mRNA of DC37, HSP90α and HSP90β 
(17 pmol each) via electroporation and cultured for 5 days. PC-3 transfected with siRNA (  × 106 cells) 
was s bcutaneously inj cted to each back of male SCID mice at 6- to 7-weeks old. The major axis (a) 
and minor axis (b) of tumors were measured with a caliper once a week until the day 99 post-injection 
period. The tumors w re deemed to b  ellipsoid and the volumes were calculated with a for ula as 
follo s:     ≒ 4πab2/3. These studies were carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the Japanese 
Pharmacological Society. The protocol was approved by the Committee on the Ethics of Animal 
Experiments of the Okayama University (Permit Number: OKU-2016219). 
2.15. Statistics 
Data were expressed as the means ± SD unless otherwise specified. Statistical significance 
was calculated using GraphPad Prism (GraphPad, La Jolla, CA, USA). Comparisons of 2 were 
done with an unpaired Student’s t-test. Three or more mean values were compared using 
ANOVA Tukey’s multiple comparisons test. 
3. Results 
3.1. CRPC-Derived EVs Induce EMT in Normal Epithelial Cells 
/ . ese st ies ere carried out in strict accordance ith
the recommendations in t e the Care and Use of Laboratory Animals of the Japanese
Pharmacological Society. The protocol was pproved by the Committee on the Ethics of Animal
Experiments of the Okayam University (Permit Number: OKU-20162 9).
2.15. Statistics
Data were expressed as the means ± SD unless otherwise specified. Statistical significance was
calculated using GraphPad Prism (GraphPad, La Jolla, CA, USA). Comparisons of 2 were done with an
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unpaired Student’s t-test. Three or more mean values were compared using ANOVA Tukey’s multiple
comparisons test.
3. Results
3.1. CRPC-Derived EVs Induce EMT in Normal Epithelial Cells
We have shown that oral cancer-derived EVs induced EMT in normal epithelial cells [48]. We
then hypothesized that cancer-derived EVs induced EMT in normal epithelial cells. We therefore
aimed to establish whether PC-3-derived EVs could alter EMT properties in the normal prostate
epithelial cell line RWPE1. E-cadherin, an established epithelial marker, was decreased by the addition
of PC-3-derived EVs in a concentration-dependent manner (5, 10, 25 or 50 µg/mL) as compared to
PBS-treated control (Figure 1A, Figure S1). In contrast, N-cadherin, an established mesenchymal
marker, was increased by the addition of PC-3-derived EVs in a concentration-dependent manner.
These data therefore suggested that PC-3-derived EVs could initiate EMT in the prostate epithelial cells.
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Figure 1. The pro-epithelial-to-mesenchymal transition (EMT) effect, proteome, and stress response 
of extracellular vesicles (EVs) released by PC-3 cells. (A) Western blot showing E-cadherin/CDH1, N-
cadherin/CDH2, and GAPDH. EVs were prepared using 200-nm pore filter devices and polymer-
Figure 1. The pro-epithelial-to-mesenchymal transition (EMT) effect, proteome, and stress response
of extracellular vesicles (EVs) released by PC-3 cells. (A) Western blot showing E-cadherin/CDH1,
N-cadherin/CDH2, and GAPDH. EVs were prepared using 200-nm pore filter devices and polymer-based
precipitation (PBP) method from culture media of PC-3. RWPE-1 cells were treated with the PC-3-derived
EV at 5, 10, 25, or 50 µg/mL or PBS for 3 days and then lysed. (B) Scores of proteins identified by
LC-MS/MS. (C) Western blot showing heat shock protein (HSP)90α and β-actin expressed in normal
prostate epithelial cells, PC-3, DU-145, and PNT2 cells. The same set of protein samples was used
previously [60]. (D) Western blot showing HSP90α, CD9, and β-actin in EVs and cells. PC-3 cells
were stimulated with heat shock stress (HSS) for 1.5 or 3 h or non-heated (NH) and then cultured in
serum-free media for 24 h to collect EVs and cell lysates.
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3.2. The Proteome of sEV Released by PC-3 Cells
To establish a protein signature of sEV released by the CRPC cells, we performed a proteomic
analysis of extracellular medium using LC-MS/MS. More than 700 protein species were thus identified,
including molecular chaperones (total score: 795.5) such as HSP90α and HSP90β, extracellular signaling
proteins (total score: 10759.0) such as thrombospondin 1, extracellular matrix (ECM) proteins (total
score: 3964.7) such as fibronectin, agrin, and tenascin, cytoskeletal proteins (total score: 2070.1) such as
actin, myosin, and keratin, ECM metabolic enzymes (total score: 1367.8), lipid and cholesterol metabolic
proteins (1574.6), coagulation factors, proteinases, proteinase inhibitors, transmembrane proteins such
as CD91/LRP1, metabolic and redox regulators, vesicle- and membrane-associated proteins such as
annexin A2 and clathrin heavy chain (HC) (Figure 1B, Table 2).
Table 2. The proteome of EVs released from PC-3 cells.
Class Summed Scores Top Hit Proteins Number of Protein Types
Extracellular signaling 10759.0 TSP1, LGALS3BP 37
ECM proteins 3964.7 Fibronectin, Agrin, Tenacin 53
Cytoskeletal 2070.1 Actin, Myosin, Keratin 40
ECM metabolic enzymes 1367.8 PLOD1, PXDN 6
Lipid and cholesterol metabolism 1574.6 ApoB, ApoA-I 9
Coagulation 1173.8 F2 4
Chaperones, HSP 795.5 HSP90-alpha, Hsp90-beta, HSP70.1 23
Proteinases, proteinase inhibitor 721.6 tPA 17
Transmembrane 582.5 CD91/LRP1, Neuropilin 1 53
Metabolism and Redox 532.7 PKM 51
Vesicle- and membrane-associated 499.6 Annexin A2, Clathrin HC 16
Translational regulators 483.8 EF2 9
Isomerases 285.4 PPIA 7
Hormones 317.4 Inhibin beta 3
Lysosome 364.5 MAN2B1 2
Histone, transcriptional, epigenetic 237.2 H4, H1.4 11
Proteasome 221.0 PSMA7 19
Molecular Traffic 218.6 KIF23 6
G proteins 172.2 RACGAP1, Rac1 13
Calcium signaling 142.8 NBD1 6
Intracellular signaling 135.8 Catenin D1 4
Kinases 133.6 PGK1 7
Phosphatase 94.5 PP2A 6
Ribosome 86.1 Ribosomal protein S28 13
Antimicrobial peptide 47.8 Dermcidin 1
Miscellaneous 340.7 PSAPL1 54
Putatively serum-derived 2673.7 C3 14
Uncharacterized proteins 1544.6 u.c.p. 155
We examined expression levels of HSP90α among normal prostate epithelial cells, PC-3, DU-145,
and PNT2 cells. HSP90α was expressed at higher levels in PC-3 and DU-145 cells compared to normal
prostate epithelial cells (Figure 1C). Next, we examined whether HSP90α could be altered in cells
and EVs or released in soluble form upon proteotoxic damage exerted by HSS at 43 ◦C. HSP90α was
abundantly released with EVs as well as non-EV extracellular HSP90 upon HSS for 1.5 or 3 h (plus
24 h recovery), while intracellular HSP90α was also increased (Figure 1D, Figure S2). As a control,
we examined CD9 in the HSS study. Vesicular CD9 was increased upon the HSS, while intracellular
levels decreased in the CRPC cells, suggesting that cellular CD9 was transmitted to EVs upon HSS.
These findings indicate that HSP90α was released with EVs in response to proteotoxic stress, while
non-vesicular HSP90α was also released in response to the HSS.
3.3. Stress Triggered Vesicle Release (200–500 nm) and Cell Morphological Changes
Next, we determined whether the size and morphology of EVs released by the CRPC cells could
be altered by HSS. Indeed, the size of EVs released from PC-3 cells without HSS was between 50 and
200 nm, while larger EVs sized between 200 and 500 nm increased in the medium upon HSS for 30 min,
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1.5 h, and 3 h (Figure 2A–D; Figure S3 and Figure S4). The morphologies of the EVs corresponded
basically to a cup-like shape, although the detailed shapes were various (Figure 2A). The prototypical
EVs found under TEM were in a cup-like shape with clear walls potentially composed of a lipid bilayer,
although the thickness of the EV walls varied (Figure 2Aa). The wall of an EV was partially thick,
which may be associated with another particle (Figure 2Ab). Membrane deformation was also seen in
some EVs (Figure 2Ac). Crescent shapes are reminiscent of membrane breakage of EVs (Figure 2Ad).
These data suggested that the EVs of 50–200 nm were released from PC-3 cells without HSS, whereas
the cells additionally released the larger EVs of 200–500 nm and membrane-damaged EVs upon stress,
as a phenotype of the stressome.
1 
 
 
Figure 2 Figure 2. Release of EVs and membrane damage upon HSS. PC-3 cells were stimulated with HSS for
0.5, 1.5, or 3 h or NH, cultured for 24 h in serum-free media, from which EVs were then collected,
and images were taken. (A) TEM images. (a), Cup-like EVs with clear walls of a potential lipid bilayer.
(b), The wall of an EV was partially thick, which may be associated with another particle. (c), Membrane
deformation was also seen in some EVs. (d), Crescent shapes are reminiscent of membrane brake of
EVs. Scale bar, 100 nm. (B) Column scatterplot analysis of particle size. n = 50, mean ± SD. ANOVA
and Tukey’s multiple comparison test was performed for statistics. **p < 0.01, ***p < 0.001 (vs. NH);
n.s., not significant. (C) Column scatterplot analysis of the rate of EV(200–500 nm) upon HSS. n = 3
(random three fields), **p < 0.01; n.s., not significant. (D) Particle diameter distribution analysis
using Zetasizer. (E) Numbers of EVs(260–300 nm), EVs(300–380 nm), and EVs(380–420 nm) per mL
conditioned medium. qNano analyzer was used for counting EVs. (F–H) Cell morphological changes
upon stress. (F) Representative images of cells. Top images were enlarged ones from the squares in the
bottom images. Arrows, round-shaped cells. Arrowheads, cells with projections (or spindle shape).
Scale, 100 µm. (G) Rate of cells with projections. (H) Rate of round-shaped cells.
Next, we examined whether numbers of EVs(260–300 nm), EVs(300–380 nm), and EVs(380–420 nm)
were altered in the conditioned media by HSS. For this purpose, we used a qNano particle analyzer.
The size of EVs tended to increase depending on the duration of HSS. The number of EVs(300–380 nm)
was 16,177,300 vesicles per mL of the conditioned medium after 1.5 h of HSS (Figure 2E), whereas
not detectable in NH and HSS(0.5 h) conditions. The number of EVs(380–420 nm) was 10,256,789
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vesicles per mL of conditioned medium after 3 h of HSS, whereas not detectable in NH, HSS(0.5 h), or
HSS(1.5 h) conditions. We also used another particle diameter analyzer ELS-8000 and confirmed that
EVs(100–500 nm) were increased after HSS for 1.5 and 3 h (Figure S4). Thus, HSS increased larger EVs
in culture supernatants of PC-3 cells as compared to the non-heated condition.
Along with the release of the stressome, the morphology of PC-3 cells was altered after HSS
(Figure 2F). The rates of round-shaped cells and cells with projections (or spindle shape) were
significantly increased after HSS (Figure 2F–H; Figure S5).
These data suggested that cells underwent EMT with the loss of intercellular adhesion and junction
under stress and stressome release was coupled with cell morphological changes.
3.4. EVs (200–500 nm) were Co-Released with LDH upon Membrane Damaging Stress
Membrane deformation and break of EVs were potentially induced by the HSS. The membrane
deformation of EVs, as well as cells, could trigger the release of HSP90 from the cells and EVs.
To establish the stress-responsive release of EVs, we next measured the protein concentration of
EVs altered by the stress. EV release was significantly increased upon HSS in terms of protein
concentration (Figure 3A). We next hypothesized that cell stress could damage cellular membrane
permitting intracellular molecules such as HSPs and lactate dehydrogenase (LDH) to leak, while EVs
such as ectosomes could be released by a physiological mechanism. To verify this, we next measured
extracellular LDH released from the CRPC cells upon HSS. The release of LDH was increased by HSS
for 3 h as compared to non-heated cells (Figure 3B–D).Cells 2020, 9, x FOR PEER REVIEW 12 of 25 
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Figure 3. Release of EVs and membrane damage upon HSS. PC-3 cells were stimulated with HSS for 0.5,
1.5, or 3 h or NH, cultured for 24 h in serum-free edia, from which EVs were then collected. (A) Release
of EVs in response to st ss. Pr tein concentratio s of EV fractions were q tified using protein
assay. The ratio compared to NH is plotted. *p < 0.05, n = 5 to 7. (B) Release of lactate dehydrogenase
(LDH) upon HSS. PC-3 cells in the sparse condition were stimulated with or without HSS for 3 h and
then LDH release was measured. (C,D) Column scatterplot analysis of LDH release. PC-3 cells were
stimulated with HSS for 0.5, 1.5, or 3 h or NH, cultured for 24 h in serum-f e media. The released LDH
was measured. Data from two independent experiments are shown in C and D. Statistical analysis
was carried out using ANOVA and Tukey’s multiple comparisons test. n = 3, ***p < 0.001, *p < 0.05,
###p < 0.001, ####p < 0.0001.
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These results indicated that HSS induced the release of LDH from the CRPC cells potentially
through membrane damage of the cells. sEV and HSP90 could be co-released with LDH upon the
membrane damage caused by HSS.
3.5. Positive Regulation of CDC37 Promoter by HSF1
CDC37 is a molecular chaperone that regulates the folding of kinases and nuclear receptors in
association with HSP90 [61,62,81]. We therefore examined the potential role of this co-chaperone in
the release of EVs. Many members of the HSP family are stress-responsive, i.e., characteristically
inducible by heat shock under the control of heat shock-responsive transcription factor 1 (HSF1) [74,82],
but also by hypoxia, and starvation stress. However, it has not been fully established whether
CDC37 was stress-inducible or not. HSF1 binds to heat shock elements (HSE: consensus sequence,
5′-GAAxxTTCxxGAA-3′ and reverse consensus sequence 5′-TTCxxGAAxxTTC-3′) in promoter regions
of target genes. We therefore searched HSE in Cdc37 genes in eukaryotes. Several HSE were scattered
around the transcription start sites (TSS) in 5′-flanking regions and gene bodies (−5000 to +1000) of
Cdc37 gene in human, mouse, and rat (Figure 4A), while HSE were more abundant in the same range
of Cdc37 gene in fission yeast. In the core promoter regions (−500 to +1) of the Cdc37 gene in these
mammals, two HSE at the −438 and −171 positions were conserved between species (Figure 4B–D).
The HSE(−438) 5′-GAAagTcCgaGgA-3′ in human CDC37 was conserved with a corresponding
HSE(−446) 5′-aAAcaTTCtaaAA-3′ in rat Cdc37, while another HSE(−171) 5′-GgAacTTCcaGAA-3′ in
mouse Cdc37 was 100% conserved with the HSE(−179) 5′-GgAacTTCcaGAA-3′ in rat Cdc37 (Figure 4E).
To examine whether the CDC37 promoter could be regulated by HSF1, we performed the reporter
assay using the CDC37 promoter-luciferase constructs. We here used DU-145 prostate adenocarcinoma
cells, in which endogenous CDC37 level was not fully induced as compared to the PC-3 cells [60].
The CDC37 promoter (500+UTR) containing the HSE(−438) was activated by HSF1 overexpression in
DU-145 cells, whereas dominant-negative HSF1 (DN-HSF1) failed to activate the CDC37 promoter
(Figure 4F,G). Moreover, another CDC37 promoter construct (200+UTR) without HSE did not respond
to HSF1 overexpression. These data indicated that HSF1 mediates cell stress signal to the CDC37 gene.
3.6. Stress-Responsive Induction of CDC37, CD9, and Extracellular HSP90α and GAPDH
We next examined whether CDC37, HSP90, and CD9 are inducible by HSS and released from PC-3
cells. As expected, CDC37 was induced by HSS (43 ◦C, 30 min), but not found in either the extracellular
or non-vesicular fractions (Figure 4H, top; Figure S6). HSP90α, a known inducible type of HSP, was
increased by HSS intracellularly, in EVs and the non-vesicular extracellular fraction (Figure 4H, second
row). HSP90β, the constitutively expressed HSP90 ortholog was increased in the EV fraction upon the
HSS, while intracellular HSP90β was decreased, suggesting that HSP90β could be transmitted from
the cells to EV fraction upon the HSS (Figure 4H, third row). CD9 was increased in the cells and the EV
fraction upon the HSS (Figure 4H, fourth row). Extracellular GAPDH was increased coordinately with
the increase of extracellular HSP90α (Figure 4H, bottom row).
These data indicated that the cell stress-induced CDC37, extracellular HSP90α and GAPDH,
and CD9-positive EVs, coordinately.
3.7. CDC37, a Stress-Responsive Protein Essential for the Release of EVs
These data prompted us to hypothesize that CDC37, although not secreted itself, could be
involved in the secretion of CD9-positive vesicles. To verify this hypothesis, we next asked whether
the CD9 levels in the cellular and EV fractions could be altered by CDC37 knockdown using siRNA.
CDC37 knockdown markedly decreased the CD9 level in the cellular and EV fractions (Figure 5A
and Figure S7). Coordinately, cellular protein concentrations per cell were significantly decreased by
CDC37 knockdown as compared to the control siRNA condition (Figure 5B). EV protein concentration
per cell was also significantly decreased by CDC37 knockdown (Figure 5C).
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Figure 4 Figure 4. Heat shock response and roles of CDC37 in vesicular protein release. (A) Promoter analysis
of Cdc37 (−5000 to +1000) in human, mouse, rat, and fission yeast. Heat shock elements (HSE) were
mapped as red boxes. (B–D) Mapping of HSE in Cdc37 core promoter regions (−500 to transcription
start site) in (B) human, (C) mouse, and (D) rat. HSEs were enclosed with red rectangles. (E) Alignment
of HSE conserved among mammals. The HSE(−438) in human CDC37 is conserved with a reverse
HSE(−446) in rat Cdc37. Another HSE(−171) in mouse Cdc37 is conserved with the HSE(−446) in rat
Cdc37. (F) Schemes of human CDC37 promoter-luciferase reporter constructs. Promoter regions (500bp
+ UTR or 200bp + UTR) were connected with luciferase gene. UTR, 5′-untranslated region. (G) Activities
of CDC37 promoter regulated by heat shock factor 1 (HSF1). The CDC37 promoter-reporter constructs
were co-transfected with overexpression constructs of HSF1 or dominant-negative (DN)-HSF1 into
DU-145 cells. *p < 0.05, n = 3. (H) Western blot showing CDC37, HSP90, CD9, and GAPDH altered by
HSS in PC-3 cells, EVs, and non-EV fraction. PC-3 cells were stimulated with or without HSS (43 °C
for 30 min), cultured in serum-free media for 24 h, and then cell lysate, EV, and non-EV fractions
were collected.
These data suggested that CDC37 was essential for proteostasis, CD9 synthesis, and the release of
CD9-containing vesicles from the CRPC cells.
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Figure 5. Inhibition of proteostasis and CD9 in EVs by the knockdo n of CDC37. The siRNA targeting
CDC37 or non-targeting control siRNA was transfected int - ells. Cell lysate and EVs were
prepared at 48 h after th transfection. (A) Western blot sho C37, CD9, and GAPDH in PC-3
cells. EVs were prepared using 200-nm pore filter devices and PBP method. (B) Cellular protein
concentration per million cells. **p < 0.01, n = 3. (C) EV protein concentration per million cells.
**p < 0.01, n = 3.
3.8. CDC37 is Essential for EMT in the CRPC Cells
HSP90α is an inducible type of HSP in stressed conditions and cancer, while HSP90β is a
constitutively expressed type of HSP [14,27]. We next examined whether both CDC37 and HSP90α could
be involved in EMT properties in PC-3 cells. We here investigated the vimentin level, a well-established
mesenchymal marker. The knockdown of CDC37 markedly decreased vimentin and increased
E-cadherin levels in the CRPC cells (Figure 6A and Figure S8), indicating that CDC37 is an essential
factor in EMT. The knockdown of HSP90α increased E-cadherin, suggesting that HSP90α is also crucial
in EMT. The knockdown of HSP90α also increased HSP90β, a potentially compensatory response in
the loss of chaperone.
Next, we examined whether CDC37 and HSP90α could be involved in the release of EVs from
PC-3 cells. The knockdown of CDC37 significantly decreased the fraction of EV protein compared
with cellular protein concentration, suggesting that EV release was inhibited by CDC37 knockdown
(Figure 6B). EVs(200–1000 nm) were reduced by the knockdown of CDC37/HSP90α (Figure S9) along
with the loss of EV protein concentration.
These data indicated that CDC37 was essential for proteostasis, EV protein release, and EMT in
prostate cancer cells.
3.9. Triple Targeting of CDC37, HSP90α, and HSP90β Declines the Tumorigenicity of CRPC In Vivo
We have experienced that knockdown of a chaperone could often trigger the compensatory
induction of another chaperone. We therefore next examined double knockdown and triple knockdown
of the chaperone trio- CDC37, HSP90α, and HSP90β. Each combination of siRNA successfully reduced
their respective targets, while triple siRNA combination markedly reduced the CDC37, HSP90α,
and HSP90β trio (Figure 6C and Figure S10). Previous studies have shown that PC-3, a CRPC cell
line, was the most tumorigenic prostate cancer cell line as compared to the other established prostate
carcinoma cell lines [4]. We next examined whether the triple knockdown of the chaperone trio (CDC37,
HSP90α, HSP90β) altered in vivo tumorigenesis of the CRPC cells. The triple knockdown of the
chaperone trio tended to inhibit in vivo tumorigenesis of PC-3 cells (Figure 6D–H). Tumor incidence
was 2/3 in the control group, while 0/3 in the triple knockdown group until day 56, suggesting the
triple knockdown of the chaperones was anti-tumorigenic.
These results indicated that members of the chaperone trio (CDC37, HSP90α, HSP90β) were
essential for tumorigenicity of the CRPC cells.
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4. Discussion
Cell extrinsic molecules secreted by both tumor and infiltrating normal cells may play key
roles in conditioning the tumor environment and enhancing malignancy. For instance, infiltrating
macrophages and fibroblasts may supply key growth factors and ECM molecules enhancing growth
and metastasis [83–85]. Tumors may also condition their environments with molecules such as HSPs to
supply essential chaperones to recipient cells and trigger receptor-mediated signaling [19,86]. However,
the exact details of the tumor chaperone network are not yet defined. Our study demonstrated that
HSP90 and CDC37 are essential for a key component of the network, stressome release which permits
the exit of HSPs and promotes tumor progression in CRPC. The release of EVs and HSP90 from the
CRPC cells was a major aspect of the resistance-associated secretory phenotype (RASP). Moreover, we
show intracellular CDC37 to be essential for EMT-coupled EV release from CRPC cells, which may
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constitute a key first step to understanding the mechanisms underlying HSP-loaded EV secretion.
There are more than 10 co-chaperones of HSP90, which individually carry out distinct cooperative roles
with HSP90 in cells [87]. CDC37 is a definitive kinome chaperone assisting in the folding of protein
kinases such as SRC, many receptor tyrosine kinases (RTK), their downstream Ras/Raf/MEK/ERK
signaling pathway, and PI3K-AKT signaling pathway, which promote EMT [88–91]. Among such
key kinases, a recent study showed that SRC in endosomal membranes promoted exosome secretion
and tumor progression [92]. Moreover, activation of the epidermal growth factor receptor (EGFR)
promoted the secretion of EGFR-rich EVs, whose transmission to recipient cells promoted EMT and
metastasis [48,93–96]. LRP1/CD91 could be another RTK, a receptor involving the kinase-specialized
CDC37/HSP90 chaperone complex and activates the MEK-ERK signaling pathway [97]. CDC37 could
positively regulate EMT and the release of EVs through permitting the function of these protein kinases.
Consistently, recent studies have shown that EMT in cancer cells was often coupled with the release of
EVs and drug resistance [22,98,99].
Our studies also touch upon the induced release of HSP90 in the CRPC cells. Several studies,
including ours, have indicated that HSP90 is essential in stress resistance in cancer cells [4,19,20,50,52].
Notably, extracellular HSP90 plays key roles in tumor progression and metastasis as well as immune
surveillance [27]. It has been shown that HSP90α was an inducible type of HSP in a stressed condition
and cancer, while HSP90β was a constitutively expressed type of HSP [14,27]. However, mechanisms
by which HSP90α or HSP90β are released from vesicles or cells had not well-investigated before
our study. We demonstrated HSP90α to be robustly inducible by HSS and efficiently released as
a cargo of EV as well as in the form of EV-free HSP90. In contrast, the HSP90β ortholog was not
markedly inducible but was transmitted to EVs upon HSS and barely dissolved in the extracellular
fluid. Notably, membrane-damaged EVs, EVs(200–500 nm), HSP90α, and GAPDH were co-released
upon HSS, suggesting that vesicular membranes were damaged by the stress, which allowed the
release of cargos, including HSP90α and GAPDH, from the damaged EVs (Figure 7, graphical abstract).
Therefore, we here define “stressome” as cell stress-induced all secretion products released from cells
and EVs. Stressome markers include EVs(200–500 nm), damaged membrane remnants, extracellular
HSPs, and extracellular GAPDH. Indeed, extracellular HSPs have been known to exhibit the functions
of DAMPs. Moreover, membrane-bound HSPs can be associated with stress-responsive EVs [27].
Otherwise, the production of ectosomes (100–500 nm) requires budding and shedding of the cell
membrane, which can create membrane damage on vesicles and cells. Moreover, it has been shown
that cell motility and stem cell properties induced by the EMT required destabilization of lipid
rafts [100]. Therefore, it is conceivable that heat shock triggers the co-release of ectosomes, HSP90,
and LDH through membrane damage of vesicles and cells and destabilization of lipid rafts. A recent
study showed that HSP90 mediated membrane deformation and exosome release [101]. In our study,
knockdown of CDC37 significantly decreased the release of EV proteins, including CD9, from the
CRPC cells. Therefore, it was conceivable that the chaperone activity of CDC37 was essential for
proteostasis and the release of sEV proteins. CD9 has been known as a marker of exosomes, small
vesicles secreted from cells via exocytosis. However, recent studies pointed out the heterogeneity of
EVs and exosomes [29,102–105]. Therefore, for example, some EVs contained many CD9, while the
other EVs might not contain CD9. Our study indicated that HSS increased CD9 in cells, involving the
increase in CDC37. However, CD9 might not be incorporated in EVs or exosomes in only 30 min of
HSS. Thus, CD9, a canonical marker of exosomes, showed different dynamics from HSP90α, a marker
of stressome.
It is also clear that the properties of 3D tumors in vivo might be largely different in many aspects
from 2D-cultured cells in vitro. Single targeting of CDC37 did not inhibit in vivo tumorigenicity,
while triple targeting of CDC37/HSP90α/HSP90β markedly inhibited tumorigenicity of CRPC cells.
Consistently, HSP90α was markedly released from 3D tumoroids of PC-3 cells, which resemble a
miniaturized tumor in vitro. Thus, the chaperone trio composed of CDC37 and HSP90α/β was crucial
for tumorigenicity of CRPC cells. Notably, the tumorigenicity of CRPC cells is a key property for
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recurrence and metastasis in this type of prostate cancer. In the androgen insensitivity, intracellular
kinase signaling pathways can be of higher priority required for tumor progression. This logic is
consistent with elevated expression of CDC37, a kinome chaperone, in CRPC as compared to prostate
adenocarcinoma and with the anti-tumor effect of the triple chaperone depletion.
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Figure 7. Graphical abstract. (A) Prostate cancer cells release EVs(50–200 nm) that contain HSP90α
and transform normal epithelial cells by inducing EMT. (B) Cellular stress such as HSS activates HSF1,
which induces the production of CDC37 and HSP90α via transcriptional activation (left). CDC37 is
essential for proteostasis and the release of CD9-containing EVs. HSS for 1.5–3 h also triggers the
production of larger EVs(200–500 nm) and membrane damage of EVs, from which HSP90α and GAPDH
could be leaked. Therefore, we here define “stressome” as cell stress-induced all secretion products
including EVs, membrane-damaged vesicles, and factors released from EVs and cells. Stressome may
promote tumor progression.
Our data also indicated that HSF1, a mediator of the stress response, positively regulates the CDC37
gene expression. We recently demonstrated that myeloid zinc finger 1 (MZF1) and SCAND1 reciprocally
regulate CDC37 gene expression in prostate cancer. In this study, a gain of MZF1, as well as a loss
of SCAND1, were crucial for CDC37 expressio . In addition, intracellular matrix metalloproteinase
(MMP) 3 as a transcription factor cooperated with HSF1-mediated stress res onse [74,78,106]. Thus,
HSF1 can coordinately activate the CDC37 gene along with other transcription factors, while especially
playing a key role in stress response and resistance. Indeed, the overexpression of a DN-HSF1 construct
inhibited aneuploidy in prostate carcinoma cells [107]. Thus, HSF1 activation of CDC37 could be
crucial for exosome release as well as EMT.
5. Conclusions
We define “stressome” as a cell stress-induced secretory program including EVs(200–500 nm),
membrane-damaged vesicles and remnants, and extracellular HSP90 and GAPDH. Our data also
indicated that CDC37 is crucial for the release of vesicular proteins and tumor progression in
prostate cancer.
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